Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer

Fenlai Tan; Yuankai Shi; Yinxiang Wang; Lieming Ding; Xiaobin Yuan; Yan Sun

doi:10.2217/fon.14.249

Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer

Fenlai Tan, Yuankai Shi, Yinxiang Wang, Lieming Ding, Xiaobin Yuan, Yan Sun

Accounting, School Of

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Advanced non-small-cell lung cancer (NSCLC) is the main cause for cancer-related mortality. Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. EGF receptor (EGFR) tyrosine kinase inhibitors gefitinib, erlotinib and afatinib came up with prolonged progression-free survival and improved quality of life, especially in EGFR-mutated patients. Icotinib is an oral selective EGFR tyrosine kinase, which was approved by China Food and Drug administration in June 2011 for treating advanced NSCLC. Its approval was based on the registered Phase III trial (ICOGEN), which showed icotinib is noninferior to gefitinib. This review will discuss the role of icotinib in NSCLC, and its potential application and ongoing investigations.

Original language	English
Pages (from-to)	385-397
Number of pages	13
Journal	Future Oncology
Volume	11
Issue number	3
DOIs	https://doi.org/10.2217/fon.14.249
State	Published - Feb 1 2015

Keywords

EGF receptor tyrosine kinase inhibitors
icotinib
molecular targeted therapy
non-small-cell lung cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon.14.249

Cite this

@article{d02fbae42e784124931f80eba2fa6781,

title = "Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer",

abstract = "Advanced non-small-cell lung cancer (NSCLC) is the main cause for cancer-related mortality. Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. EGF receptor (EGFR) tyrosine kinase inhibitors gefitinib, erlotinib and afatinib came up with prolonged progression-free survival and improved quality of life, especially in EGFR-mutated patients. Icotinib is an oral selective EGFR tyrosine kinase, which was approved by China Food and Drug administration in June 2011 for treating advanced NSCLC. Its approval was based on the registered Phase III trial (ICOGEN), which showed icotinib is noninferior to gefitinib. This review will discuss the role of icotinib in NSCLC, and its potential application and ongoing investigations.",

keywords = "EGF receptor tyrosine kinase inhibitors, icotinib, molecular targeted therapy, non-small-cell lung cancer",

author = "Fenlai Tan and Yuankai Shi and Yinxiang Wang and Lieming Ding and Xiaobin Yuan and Yan Sun",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = feb,

day = "1",

doi = "10.2217/fon.14.249",

language = "English",

volume = "11",

pages = "385--397",

journal = "Future Oncology",

issn = "1479-6694",

number = "3",

}

TY - JOUR

T1 - Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer

AU - Tan, Fenlai

AU - Shi, Yuankai

AU - Wang, Yinxiang

AU - Ding, Lieming

AU - Yuan, Xiaobin

AU - Sun, Yan

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Advanced non-small-cell lung cancer (NSCLC) is the main cause for cancer-related mortality. Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. EGF receptor (EGFR) tyrosine kinase inhibitors gefitinib, erlotinib and afatinib came up with prolonged progression-free survival and improved quality of life, especially in EGFR-mutated patients. Icotinib is an oral selective EGFR tyrosine kinase, which was approved by China Food and Drug administration in June 2011 for treating advanced NSCLC. Its approval was based on the registered Phase III trial (ICOGEN), which showed icotinib is noninferior to gefitinib. This review will discuss the role of icotinib in NSCLC, and its potential application and ongoing investigations.

AB - Advanced non-small-cell lung cancer (NSCLC) is the main cause for cancer-related mortality. Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. EGF receptor (EGFR) tyrosine kinase inhibitors gefitinib, erlotinib and afatinib came up with prolonged progression-free survival and improved quality of life, especially in EGFR-mutated patients. Icotinib is an oral selective EGFR tyrosine kinase, which was approved by China Food and Drug administration in June 2011 for treating advanced NSCLC. Its approval was based on the registered Phase III trial (ICOGEN), which showed icotinib is noninferior to gefitinib. This review will discuss the role of icotinib in NSCLC, and its potential application and ongoing investigations.

KW - EGF receptor tyrosine kinase inhibitors

KW - icotinib

KW - molecular targeted therapy

KW - non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84923081541&partnerID=8YFLogxK

U2 - 10.2217/fon.14.249

DO - 10.2217/fon.14.249

M3 - Article

C2 - 25675121

AN - SCOPUS:84923081541

SN - 1479-6694

VL - 11

SP - 385

EP - 397

JO - Future Oncology

JF - Future Oncology

IS - 3

ER -

Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this